Since SCN1A mutations impair Nav1.1 sodium channels, which are critical for neuronal signaling, particularly in inhibitory interneurons, sodium channel blockers—a common type of anti-epileptic drugs—are generally ineffective for DS and should be avoided. This evidence concerns the gene SCN1A and Dravet syndrome.